Patents by Inventor Garry Paul Duffy

Garry Paul Duffy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mesenchymal stem cell for promoting neovascularisation
    Patent number: 8617883
    Abstract: The Eph (erythropoietin-producing hepatocellular carcinoma) receptors and their cell surface anchored ligands, the Ephrins, comprise the largest of the receptor tyrosine kinases families with 14 receptors and 8 ligands. The receptors are subdivided into Eph-A and Eph-B categories and have known actions in the development of the vascular and nervous system. The present invention relates to an isolated mesenchymal stem cell selected from the group consisting of an isolated mesenchymal stem cell that expresses Ephrin-B2, an isolated mesenchymal stem cell that over-expresses Ephrin-B2, and an isolated mesenchymal stem cell that is genetically modified to increase Ephrin-B2 expression. The invention further relates to the various applications of the isolated mesenchymal stem cells of the present invention.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: December 31, 2013
    Assignee: National University of Ireland, Galway
    Inventors: Garry Paul Duffy, Frank Barry, Timothy O'Brien
  • STEM CELL SOURCE FOR PROMOTING NEOVASCULARISATION
    Publication number: 20100028401
    Abstract: The Eph (erythropoietin-producing hepatocellular carcinoma) receptors and their cell surface anchored ligands, the Ephrins, comprise the largest of the receptor tyrosine kinases families with 14 receptors and 8 ligands. The receptors are subdivided into Eph-A and Eph-B categories and have known actions in the development of the vascular and nervous system. The present invention relates to an isolated mesenchymal stem cell selected from the group consisting of an isolated mesenchymal stem cell that expresses Ephrin-B2, an isolated mesenchymal stem cell that over-expresses Ephrin-B2, and an isolated mesenchymal stem cell that is genetically modified to increase Ephrin-B2 expression. The invention further relates to the various applications of the isolated mesenchymal stem cells of the present invention.
    Type: Application
    Filed: July 31, 2008
    Publication date: February 4, 2010
    Inventors: Garry Paul Duffy, Frank Barry, Timothy O'Brien